Endocannabinoid structure-activity relationships for interaction at the cannabinoid receptors

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 66, Issue 2-3, 2002, Pages 143-160

  Reggio, P H ^a  

^a KENNESAW STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHDINOYLGLYCEROL ETHER; 2 ARACHIDONOYLGLYCEROL; AMINE; ANANDAMIDE; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR; DOCOSATETRAENYLETHANOLAMIDE; ETHANOLAMINE DERIVATIVE; ETHER DERIVATIVE; FATTY ACID; FATTY ACID AMIDASE; FATTY ACID ESTER; HOMO GAMMA LINOLENYLETHANOLAMIDE; HYDROLASE; N 7,10,13,16 DOCOSATETRAENYLETHANOLAMINE; PALMIDROL; UNCLASSIFIED DRUG; CANNABINOID; DRUG RECEPTOR; ENDOCANNABINOID; ICOSANOID;

ACTIVE TRANSPORT; ANIMAL CELL; ANIMAL TISSUE; CELLULAR DISTRIBUTION; CONFORMATION; DRUG ACTIVITY; DRUG ISOLATION; DRUG RECEPTOR BINDING; ENZYME BINDING; ENZYME LOCALIZATION; HYDROLYSIS; LIGAND BINDING; MEMBRANE BINDING; MOLECULAR INTERACTION; MOLECULAR RECOGNITION; NEUROPHARMACOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN INTERACTION; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG POTENTIATION; ENZYME SPECIFICITY; METABOLISM;

HOMO;

ANIMALS; CANNABINOIDS; EICOSANOIDS; ENDOCANNABINOIDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 0036019384     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1054/plef.2001.0343     Document Type: Article

References (140)

1. Isolation and structure of a brain constituent that binds to the cannabinoid receptor
2. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice
3. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): Identification of cannabinoid receptor subtype selective ligands
4. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor
5. Formation and inactivation of endogenous cannabinoid anandamide in central neurons
6. Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells
7. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP
8. Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachinonoyl phosphatidylethanolamine, in rat brain
9. Cannabinoid receptor receptor agonist efficacy for stimulating [35 S]GTPγS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity
10. Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1)
11. Ananadamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase
12. Effects of anandamide on cannabinoid receptors in rat brain membranes
13. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction
14. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors
15. Endocannabinoid 2-arachidonylglycerol is a full agonist through human type 2 cannabinoid receptor: Antagonism by anandamide
16. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells
17. Cannabinoids activate inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabiniod receptor
18. Cannabinoid receptors can activate and inhibit G protein-coupled inwardly rectifying potassium channels in a Xenopus oocyte expression system
19. Regulation of a neuronal form of focal adhesion kinase by anandamide
20. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1
21. Signalling pathway associated with stimulation of the CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinases and the induction of Krox-24 expression
22. The MAP kinase signal transduction pathway is activated by the endogenous cannabinoid anadamide
23. Arachidonylethanolamide (AEA) activation of FOS proto-oncogene protein immunoreactivity in the rat brain
24. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation
25. Cannabinoid receptors are coupled to nitric oxide release in invertebrate immunocytes, microglia, and human monocytes
26. Morphine and anandamide coupling to nitric oxide stimulates GnRH and CRF release from rat median eminence: Neurovascular regulation
27. Antagonism of LPS and IFN-induction of iNOS in human saphenous vein endothelium by morphine and anandamide by nitric oxide inhibition of adenylate cyclase
28. Morphine and anandamide stimulate intracellular calcium transients in human endothelial cells: Coupling to nitric oxide release
29. 2+ in endothelial cells
30. Accumulation of n-arachidonylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion
31. Functional role of high-affinity anandamide transport, as revealed by selective inhibition
32. Structural determinants for recognition and translocation by the anandamide transporter
33. Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells
34. Anandamide amidohydro lase activity in rat brain microsomes
35. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
36. Fatty acid amide hydrolase, the degradative enzyme for anandamide and oleamide has selective distribution in neurons within the rat central nervous system
37. A new perspective on cannabinoid signalling: Complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain
38. Immunocytochemical localization of cannabinoid CB1 receptor and fatty acid amide hydrolase in rat retina
39. The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase
40. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors
41. 2-Arachidonylglycerol: A possible endogenous cannabinoid receptor ligand in brain
42. Second endogenous cannabinoid that modulates long-term potentiation
43. Structural requirements for arachidonylethanolamide interaction with CB1 and CB2 cannabinoid receptors: Pharmacology of the carbonyl and ethanolamide groups
44. 2+ in neuroblastoma x glioma hybrid NG108-15 cells
45. 2+ transient in NG 108-15 cells
46. Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds
47. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or annadamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various receptor ligands in HL-60 cells
48. 2-Arachidonoylglycerol and the cannabinoid receptors
49. Structure-activity relationships among anandamide head group analogs for the anandamide transporter
50. Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand
51. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses
52. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor
53. Carbachol, an acetylcholine receptor agonist, enhances production in rat aorta of 2-arachidonoyl glycerol, a hypotensive endocannabinoid
54. Synthesis and biological activities of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, and its metabolically stable ether-linked analogues
55. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide
56. N-(2-hydroxyethyl) hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation
57. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells
58. Characterization of the kinetics and distribution of N-arachidonylethanolamine (anandamide) hydrolysis by rat brain
59. Reversible hydrolysis and synthesis of anandamide demonstrated by recombinant rat fatty-acid amide hydrolase
60. Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells
61. The novel endogenous cannabinoid 2-arachidonylglycerol is inactivated by neuronal- and basophil- like cells: Connections with anandamide
62. Molecular characterization of human and mouse fatty acid amide hydrolases
63. Anandamide hydrolysis by human cells in culture and brain
64. Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase
65. An endogenous sleep-inducing compound is a novel competitive inhibitor of fatty acid amide hydrolase
66. Inhibitors of arachidonoyl ethanolamide hydrolysis
67. Inhibition of oleamide hydrolase catalyzed hydrolysis of the endogenous sleep-inducing lipid cis-9-octadecenamide
68. Trifluormethyl ketone inhibitors of fatty acid amide hydrolase: A probe of structural and conformational features contributing to inhibition
69. Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor
70. Methyl arachidonyl fluorophosphonate: A potent irreversible inhibitor of anandamide amidase
71. Chemical characterization of a family of brain lipids that induce sleep
72. Novel inhibitors of brain, neuronal, and basophilic anandamide amidohydrolase
73. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist
74. Novel analogues of arachidonylethanolamide (anandamide): Affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability
75. Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor
76. Molecular characterization of a peripheral receptor for cannabinoids
77. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons
78. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations
79. Cannabinoid receptor binding and agonist activity of amides and esters of arachidonic acid
80. (R)-Methanandamide; a chiral novel anandamide possessing higher potency and metabolic stability
81. Stereochemical selectivity of methanandamides for the CB1 and CB2 cannabinoid receptors and their metabolic stability
82. Pharmacological and behavioral evaluation of alkylated anandamide analogs
83. Natural and synthetic endocannabinoids and their structure-activity relationships
84. Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase
85. Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs
86. Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand
87. The binding of novel phenolic derivatives of anandamide to brain cannabinoid receptors
88. N-acyl dopamines: Novel synthetic CB1 cannabinoid receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo
89. Unique analogues of anandamide: Arachidonyl ethers and carbamates and norarachidonyl carbamates and ureas
90. Crystal structure of the C form of stearic acid
91. The structures of the essential unsaturated fatty acids. Crystal structure of linoleic acid and evidence for the crystal structures of α-linolenic and arachidonic acid
92. Adipocyte lipid-binding protein complexed with arachidonic acid. Titration calorimetry and X-ray crystallographic studies
93. The productive conformation of arachidonic acid bound to prostaglandin synthase
94. On the conformational, physical properties and functions of polyunsaturated acyl chains
95. Conformational analysis of arachidonic and related fatty acids using molecular dynamics simulations
96. Lipid mimetics: The design and properties of conformationally-restricted arachidonic acid lipidic and peptidic analogues
97. Conformational search and transitional states study of arachidonic acid using molecular dynamics and AM1 semi-empirical calculations
98. Automated conformational analysis: Directed conformational search using the A* Algorithm
99. The adipocyte lipid-binding protein at 1.6 angstroms resolution: Crystal structures of the apoprotein and with bound saturated and unsaturated fatty acids
100. Computer-based modeling of the conformation and packing properties of docosahexaenoic acid
101. Studies on the conformational mobility of arachidonic acid. Facile macrolactonization of 20-hydroxyarachidonic acid
102. Selective epoxidation of eicosa-cis-5, 8,11,14 tetraenoic (arachidonic) acid and eicosa-cis-8,11,14-trienoic acid
103. Conformational analysis of flexible molecules: Location of the global minimum conformation by the simulated annealing method
104. The binding of arachidonic acid in the cyclooxygenase active site of mouse prostaglandin endoperoxidase synthase -2 (COX-2)
105. A theoretical conformational analysis of the complex of tocopherol and arachidonic acid molecules
106. Conformational memories and the exploration of biologically relevant peptide conformations: An illustration for the gonadotropin-releasing hormone
107. 4
108. Exploration of biologically relevant conformations of anandamide, 2-arachidonylglycerol and their analogs using conformational memories
109. Evaluation of cannabimimetic effects of structural analogs of anandamide in rats
110. Conformational requirements for endocannabinoid interaction with the anandamide transporter and the fatty acid amidohydrolase
111. Structure-activity analysis of anandamide analogs: Relationship to a cannabinoid pharmacophore
112. Synthesis and pharmacological comparison of dimethyl-heptyl and pentyl analogs of anandamide
113. Potent anandamide analogs: The effect of changing the length and branching of the end pentyl chain
114. Derivation of a pharmacophore model for anandamide using constrained conformational searching and comparative molecular field analysis
115. Structure-activity relationships in cannabinoids
116. Cannabinoid structure-activity relationships: Correlation of receptor binding and in vivo activities
117. Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonyl-ethanolamide (anandamide): Their affinities for cannabinoid receptors and pathways of inactivation
118. Synthesis and cannabinoid receptor binding activity of conjugated triene anandamide, a novel eicosanoid
119. Investigation of structural analogs of prostaglandin amides for binding to and activation of CB1 and CB2 cannabinoid receptors in rat brain and human tonsils
120. Investigation of structural analogs of anandamide for binding and activation of cannabinoid receptors
121. Conformational requirements for CB1/endocannabinoid interaction
122. Agonist alkyl tail interaction with cannabinoid CB1 receptor V6.43/I6.46 groove induces a helix 6 active conformation
123. Activation of the β2 adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6
124. Agonist-induced conformational changes at the cytoplasmic side of TM 6 in the β2 adrenergic receptor mapped by site-selective fluorescent labeling
125. Requirement of rigid-body motion of transmembrane helicies for light activation of rhodopsin
126. A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonist, but not WIN-55,212
127. Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB2 cannabinoid, as potential ligands for the cannabinoid receptors
128. Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide
129. 2 receptor mediated behavior in the rat by oleamide and the role of cannabinoid receptors
130. Cerebrodiene, arachidonyl-ethanolamide, and hybrid structures: Potential for interaction with brain cannabinoid receptors
131. Anandamide may mediate sleep induction
132. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide
133. Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens
134. The anandamide transport inhibitor AM404 activates vanilloid receptors
135. Interactions between synthetic vanilloids and the endogenous cannabinoid system
136. Unsaturated long-chain N-acyl-vanillylamides (N-AVAMs): Vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors
137. Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide
138. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: Inhibitors of anandamide uptake with negligible capsaicin-like activity
139. Highly selective CB1 cannabinoid receptor ligands and novel CB1/VR1 vanilloid receptor 'hybrid' ligands